US halts AstraZeneca vaccine production at Baltimore plant, NYT says

Published: Updated:

The U.S. Health and Human Services Department on Saturday stopped a Baltimore manufacturer from making AstraZeneca Plc’s Covid-19 vaccine, days after the facility ruined 15 million doses of shots developed by Johnson & Johnson, the New York Times reported, citing two senior federal health officials who weren’t identified.

Visit our dedicated coronavirus site here for all the latest updates.

The move came after the Maryland-based biotech firm, Emergent BioSolutions Inc., accidentally mixed up the ingredients from the two vaccines, which forced regulators to delay approval of the plant’s output, the newspaper said.

The department also requested Johnson & Johnson to install a new team to oversee all aspects of manufacturing at the facility, the newspaper said, citing the officials. The company confirmed the changes and that it was “assuming full responsibility, NYT said.

AstraZeneca will work with the Biden administration to find an alternative site, the paper said, citing the drugmaker.

For all the latest headlines follow our Google News channel online or via the app.

Read more:

UK regulator found 30 cases of blood clot events after AstraZeneca vaccine use

Netherlands halts use of AstraZeneca vaccine for people under 60

Canada suspends AstraZeneca vaccine for people under age of 55

German state suspends AstraZeneca COVID-19 vaccine use for under-60s